Japanese drugmaker Eisai Co. Ltd. said on Monday it had submitted a marketing authorization application in Japan for its Alzheimer’s drug lecanemab, which was recently granted accelerated ...

TOKYO -- Japanese drugmaker Eisai will make its Alzheimer's disease treatment Leqembi available for at-home administration by fiscal 2025 in the U.S., where thousands of patients are waiting to ...

ALL RIGHT, WE HAVE THREE STATIONS TODAY. WE HAVE CHARADES, PICTIONARY AND CORNHOLE. 17 YEAR OLD ANDOVER HIGH SCHOOL JUNIOR JORDAN SHIRLEY IS A NATURAL BORN LEADER. SHE’S USING THOSE LEADERSHIP ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

E-2086 is under clinical development by Eisai and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 80% phase transition success rate (PTSR) indication ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success rate ...

ANDOVER, Kan. (KSNW) — Andover is rolling out their new $30,000 branding plan, logo included. The new logo was unveiled on the city’s Facebook page to controversy from some in Andover.

WICHITA, Kan. (KWCH) - Update: The City of Andover said Andover Fire-Rescue worked closely with a chemist from Sherwin-Williams to help extinguish the fire because it involved hazardous materials.

WICHITA, Kan. (KWCH) - UPDATE 4:10 A.M.: The Kansas Turnpike Authority confirms I-35 has reopened between Wichita and Andover. The Kansas Turnpike is closed between Wichita and Andover early ...

The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...

WICHITA, Kan. (KSNW) — First responders worked to extinguish a chemical fire in Andover early Friday. It started around 1 a.m. at the Sherwin-Williams manufacturing plant at one of the facility ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) for lecanemab-irmb (Leqembi) subcutaneous autoinjector (SC-AI ...